Matica Biotechnology to build new Cell and Gene Therapy production unit in Texas

Matica Biotechnology, a US-based contract development and manufacturing organization (CDMO) specializing in the commercial production of cell and gene therapies, broke ground on its new facility, which is said to be 25,000 square feet that will house its GMP virus production suites. The firm has stated that it will also have development laboratories and company offices. The new building will be located in Providence Park in Texas.

Since there is a massive demand for virus products, it continues to outpace production capacity under the most stringent Good Manufacturing Practices (GMP) required as per the regulatory agencies for human use. The all-new facility offered by Matica Biotechnology will help its users to close that gap by establishing state-of-the-art and modern virus production rooms that are integrated with the latest vector-based technologies.

The firm's new cleanrooms for the production of virus-based vectors will maximize speed, flexibility, and efficiency throughout the process throughout the development cycle. The availability of skilled professionals and workforce from the Texas A&M University System will rapidly increase job growth throughout the sector in the next few years. This will also improve the quality of vector production in a limited period of time.